An Egyptian research team has developed a new method to enhance the effectiveness of Vitamin D3 in children with Autism Spectrum Disorder (ASD) by creating a liquid nano-emulsion formulation that increases vitamin absorption in the body, resulting in significant improvement in core symptoms of the disorder.

The Daily Mail highlighted the study offering an innovative treatment for ASD patients, noting that Egyptian researchers developed a solution containing tiny droplets of olive oil loaded with the vitamin.

These ultra-small particles do not require a fatty meal for absorption, ensuring higher efficiency in delivering the vitamin into the bloodstream.

Details of the Egyptian Study

The research team from the National Research Centre published their study titled “Improvement of Core Autism Features After Supplementation with Nano-Emulsion Loaded Vitamin D3” in the journal LabMed Discovery.

The trial involved 80 children aged 3 to 6 years, divided into two groups: one received traditional Vitamin D3, and the other received the nano-emulsion solution. After six months, vitamin levels in the blood increased by 141% in the nano group compared to only 54% in the traditional group.

The study observed that children in the nano-emulsion group showed a marked decrease in symptom severity on the CARS scale, improved social communication, leaps in language abilities, comprehension and expression, and progress in fine motor skills and adaptive behaviors.

The study team stated: “Supplementation of children with autism using nano-loaded Vitamin D3 led to reduced symptom severity and increased social intelligence and language abilities without side effects.”

They added that this form of vitamin clearly outperforms available commercial preparations.

Challenges Facing the New Treatment

The study may open the door to a new therapeutic strategy for children with autism, but its path to medical approval is still long. Despite promising results, the technology faces regulatory and practical obstacles.

The challenges include the higher cost of producing nano-emulsions and the need for strict quality control. Moreover, the U.S. Food and Drug Administration (FDA) will treat it as an innovative drug system rather than a dietary supplement, requiring large-scale clinical trials to prove long-term safety and efficacy.